Bibliography: Neurocognitive Disorders in Geriatric Psychiatry

Cheng ST: Cognitive reserve and the prevention of dementia: the role of physical and cognitive activities. Curr Psychiatry Rep 2016; 18:85Crossref, Google Scholar

Dubois B, Hampel H, Feldman HH, et al.: The preclinical state of AD: preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 2016; 12:292–323Crossref, Google Scholar

Leonpacher AK, Peters ME, Drye LT, et al.: Effects of citalopram on neuropsychiatric symptoms in Alzheimer’s dementia: evidence from the CitAD Study. Am J Psychiatry 2016; 173:473–480Crossref, Google Scholar

Martinez-Fernández R, Schmitt E, Martinez-Martin P, et al.: The hidden sister of motor fluctuations in Parkinson’s disease: a review on nonmotor fluctuations. Mov Disord 2016; 31:1080–1094Crossref, Google Scholar

Qiu WQ, Zhu H, Dean M, et al.: Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer’s disease. Int J Geriatr Psychiatry 2016; 31:316–322Crossref, Google Scholar

Reus VI, Fochtmann LJ, Eyler AE, et al: The American Psychiatric Association (2016) Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Am J Psychiatry 2016; 173:543–546 [executive summary; full guideline at http://psychiatryonline.org/guidelines]Google Scholar

Safarpour D, Willis AW: Clinical epidemiology, evaluation, and management of dementia in Parkinson disease. Am J Alzheimers Dis Other Demen 2016; 31:585–594Crossref, Google Scholar

Stankovic I, Stefanova E, Tomic A, et al.: Psychiatric symptoms in the initial motor stage of Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2016; 28:205–210Crossref, Google Scholar

Bang J, Spina S, Miller BL: Frontotemporal dementia. Lancet 2015; 386:1672–1682Crossref, Google Scholar

Bertens D, Knol DL, Scheltens P, et al.: Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer’s disease. Alzheimers Dement 2015; 11:511–522Crossref, Google Scholar

Cohen CI, Meesters PD, Zhao J: New perspectives on schizophrenia in later life: implications for treatment, policy, and research. Lancet Psychiatry 2015; 2:340–350Crossref, Google Scholar

Edmonds EC, Delano-Wood L, Galasko DR, et al.: Subtle cognitive decline and biomarker staging in preclinical Alzheimer’s disease. J Alzheimers Dis 2015; 47:231–242Crossref, Google Scholar

Hunsberger JG, Rao M, Doraiswamy PM et al.. Accelerating stem cell trials for Alzheimer's disease. Lancet Neurol 2015 Dec 15; pii: S1474-4422(15)00332-4Google Scholar

Kalache SM, Mulsant BH, Davies SJ, et al.: The impact of aging, cognition, and symptoms on functional competence in individuals with schizophrenia across the lifespan. Schizophr Bull 2015; 41:374–381Crossref, Google Scholar

Kim YH, Choi SH, D’Avanzo C, et al.: A 3D human neural cell culture system for modeling Alzheimer’s disease. Nat Protoc 2015; 10:985–1006Crossref, Google Scholar

Lavretsky H, Reinlieb M, St Cyr N, et al.: Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; 172:561–569Crossref, Google Scholar

Ngandu T, Lehtisalo J, Solomon A, et al.: A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015; 17:2255–2263Crossref, Google Scholar

O’Brien JT, Thomas A: Vascular dementia. Lancet 2015; 386:1698–1706Google Scholar

Shmukler AB, Gurovich IY, Agius M, et al.: Long-term trajectories of cognitive deficits in schizophrenia: A critical overview. Eur Psychiatry 2015; 30:1002–1010Crossref, Google Scholar

Walker Z, Possin KL, Boeve BF, et al: Lewy body dementias. Lancet 2015; 386:1683–1697Google Scholar

Wang HF, Yu JT, Tang SW, et al.: Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015; 86:135–143Crossref, Google Scholar

Weiner MW, Veitch DP, Aisen PS, et al.: Impact of the Alzheimer’s Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement 2015; 11:865–884Crossref, Google Scholar

Bartels SJ, Pratt SI, Mueser KT, et al.: Long-term outcomes of a randomized trial of integrated skills training and preventive healthcare for older adults with serious mental illness. Am J Geriatr Psychiatry 2014; 22:1251–1261Crossref, Google Scholar

Doody RS, Farlow M, Aisen PS: Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease: Alzheimer’s Disease Cooperative Study Data Analysis and Publication Committee. N Engl J Med 2014; 370:1460Google Scholar

Doraiswamy PM, Sperling RA, Johnson K, et al.: AV45-A11 Study Group; AV45-A11 Study Group. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry 2014; 19:1044–1051Crossref, Google Scholar

Harvey PD: What is the evidence for changes in cognition and functioning over the lifespan in patients with schizophrenia? J Clin Psychiatry 2014; 75(Suppl 2):34–38Crossref, Google Scholar

Marras C, Troster AI, Kulisevsky J, et al.: The tools of the trade: a state of the art “How to Assess Cognition” in the patient with Parkinson's disease. Movement Disorders 2014; 29:584–596Crossref, Google Scholar

Porsteinsson AP, Drye LT, Pollock BG, et al.: Effect of citalopram on agitation in Alzheimer disease: the CITAD randomized clinical trial. JAMA 2014; 311:682–691Crossref, Google Scholar

Rabins PV, Rovner BW, Rummans T, et al: Guideline Watch: Practice Guideline for the Treatment of Patients With Alzheimer’s Disease and Other Dementias. Arlington, VA, American Psychiatric Association, Oct 2014. http://psychiatryonline.org/guidelinesGoogle Scholar

Rahimi J, Kovacs GG: Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther 2014; 6:82Crossref, Google Scholar

Rajji TK, Miranda D, Mulsant BH: Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies. Can J Psychiatry 2014; 59:13–17Crossref, Google Scholar

Salloway S, Sperling R, Fox NC, et al.: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014; 370:322–333Crossref, Google Scholar

Vann Jones SA, O’Brien JT: The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2014; 44:673–683Crossref, Google Scholar

Bateman RJ, Xiong C, Benzinger TL, et al.: Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012; 367:795–804Crossref, Google Scholar

Clark CM, Pontecorvo MJ, Beach TG, et al.: Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol 2012; 11:669–678Crossref, Google Scholar

Devanand DP, et al.: Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med 2012; 367:1497–1507Crossref, Google Scholar

Jack CR Jr, Albert MS, Knopman DS, et al.: Introduction to the recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:257–262Crossref, Google Scholar

Litvan I, Aarsland D, Adler CH, et al.: MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord 2011; 26:1814–1824Crossref, Google Scholar

McKhann GM, Knopman DS, Chertkow H, et al.: The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:263–269Crossref, Google Scholar

Prince M, et al.: The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9:63–75.e2Crossref, Google Scholar

Small GW, Siddarth P, Kepe V, et al.: Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol 2012; 69:215–222Crossref, Google Scholar

Sperling RA, Aisen PS, Beckett LA, et al.: Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:280–292Crossref, Google Scholar

Sperling RA, Jack CR Jr, Black SE, et al.: Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011; 7:367–385Crossref, Google Scholar

Stern Y: Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol 2012; 11:1006–1012Crossref, Google Scholar